Shareholders meeting

Date: August 04, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoi Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS Sub: Notice for convening 34th Annual General Meeting Dear Sir/Madam, Kindly find enclosed herewith the notice for convening the 34th Annual General Meeting (AGM) of the Company scheduled to be held on Thursday, August 27, 2026 at 11:00 A.M. through Video Conferencing / Other Audio Visual Means (VC/OAVM) facility. The Company is providing e-voting facility to its shareholders, in respect of all shareholders resolutions, to be passed at the AGM. The e-voting period will start on Monday, August 24, 2026 at 09:00 A.M. and will end on Wednesday, August 26, 2026 at 05:00 P.M. The facility for voting through the e-voting system will also be made available during the AGM. Members attending the AGM through VC / OAVM facility who have not cast their vote by remote e-voting will be able to vote during the AGM. The 34th AGM Notice can also be accessed on the Company’s website at https://www.marksanspharma.com/pdf/notice-of-34th-agm.pdf We request you to take the aforesaid on records. Thanking You. Yours faithfully, For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl.: As Above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com Notice Marksans Pharma Limited CIN: L24110MH1992PLC066364 Regd. Office: 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (West), Mumbai – 400053 Phone. No. 022-40012000 E-mail: companysecretary@marksanspharma.com Website: www.marksanspharma.com NOTICE The Members of Marksans Pharma Limited NOTICE is hereby given that the Thirty-Fourth (34th) Annual General “RESOLVED THAT pursuant to the provisions of Sections Meeting of the Members of Marksans Pharma Limited will be held on 196, 197 and other applicable provisions, if any, of the Thursday, 27 August 2026 at 11:00 am through video conferencing Companies Act, 2013 read with Schedule V of the said / other audio-visual means (VC), to transact the following businesses: Act and the rules made thereunder, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory ORDINARY BUSINESS modifications or re-enactment thereof for the time being in 1. To receive, consider and adopt force), and on the basis of recommendation of Nomination and Remuneration Committee, re-appointment of Mrs. Sandra a) the Audited Standalone Financial Statements of the Saldanha (DIN: 00021023) as a Whole-time Director of the Company for the Financial Year ended 31 March 2026, Company be and is hereby approved for a further period of comprising of the Audited Standalone Balance Sheet as Three (3) years with effect from 25th September, 2026 on the at 31 March 2026, the Statement of Standalone Profit following remuneration: & Loss and Standalone Cash Flow Statement for the Financial Year 01 April 2025 to 31 March 2026 including its Schedules and the Notes attached thereto and Amount in Particulars forming part thereof along with the reports of the Board J Per Month of Directors and the Statutory Auditors thereon; and Basic 2,95,000.00 Special Allowance 2,54,654.00 b) the Audited Consolidated Financial Statements of the Leave Travel Allowance 1,000.00 Company for the Financial Year ended 31 March 2026, Medical Allowance 1,250.00 comprising of the Audited Consolidated Balance Sheet Provident Fund (12%) 35,400.00 as at 31 March 2026, the Statement of Consolidated Gratuity (4.81%) 14,190.00 Profit & Loss and Consolidated Cash Flow Statement Total Remuneration Per Month 6,01,494.00 for the Financial Year 01 April 2025 to 31 March 2026 Total Remuneration Per Annum 72,17,928.00 including its Schedules and the Notes attached thereto and forming part thereof along with the reports of the “RESOLVED FURTHER THAT Mrs. Sandra Saldanha shall Statutory Auditors thereon. be provided with Company’s car with driver for use in company’s business.” 2. To declare dividend on equity shares recommended by the Board of Directors at its meeting held on 26 May 2026. The “RESOLVED FURTHER THAT remuneration payable to Board of Directors has recommended final dividend of H 0.90 Mrs. Sandra Saldanha shall be subject to deduction of tax as (90%) per equity share of Re. 1/- each face value. per the provisions of the Income Tax Act.” 3. To appoint a director in place of Dr. Sunny Sharma (DIN: “RESOLVED FURTHER THAT the remuneration payable to 02267273) who retires by rotation and being eligible, offers Mrs. Sandra Saldanha shall not exceed the limits laid down himself for re-appointment. in Section 197 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013.” SPECIAL BUSINESS “RESOLVED FURTHER THAT in case in any financial year 4. To approve the re-appointment of and remuneration to during the currency of the tenure of Mrs. Sandra Saldanha, Mrs. Sandra Saldanha (DIN: 00021023) as a Whole-time Director the Company has no profit or its profits are inadequate, the and in this regard to consider and if thought fit, to pass the Company will pay remuneration as specified above as the following resolution as Special Resolution: minimum remuneration, provided that the total remuneration Marksans Pharma Limited 239 shall not exceed the ceiling as provided in Section II of Part II of “RESOLVED FURTHER THAT any of the Directors of the Schedule V of the Companies Act, 2013.” Company and Key Managerial Personnel of the Company be and are hereby authorized severally to do all such acts, “RESOLVED FURTHER THAT the Board of Directors of the deeds and things as may be required to give effect to the Company be and is hereby authorised to increase or revise the above resolutions.” remuneration of Mrs. Sandra Saldanha during her tenure within the limits laid down in Section 197 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013.” Place: Mumbai For and on behalf of the Board of Directors of Dated: 03 July 2026 Marksans Pharma Limited Registered Office: Sd/- 11th Floor, Grandeur Harshavardhan Panigrahi Veera Desai Extension Road Company Secretary Oshiwara, Andheri (West) Mumbai - 400053 240 Annual Report 2025-26 Notice NOTES: with the Company’s RTA through website link at https://www. bigshareonline.com//InvestorRegistration.aspx. i. The 34th Annual General Meeting (AGM) is being held through Video Conferencing (“VC”) or Other Audio Visual Means vi. In line with MCA Circulars and circulars issued by SEBI, the (“OAVM”) in accordance with the General Circular Nos. 14/2020, Notice calling the AGM along with the Report is being sent 17/2020, 20/2020, dated 8th April 2020, 13th April 2020, 5th May, through electronic mode to those Members whose e-mail 2020 respectively and subsequent circulars issued in this addresses are registered with the Company/Depositories. regard, the latest being circular dated September 22, 2025 A Member can request for a physical copy of the Report by issued by the Ministry of Corporate Affairs and Circular SEBI/ sending an e-mail to the Company at companysecretary@ HO/CFD/PoD-2/P/CIR/2024/133 dated October 3, 2024 issued marksanspharma.com. Members may note that the Report will by SEBI in relation to “Clarification on holding of AGM through also be available on the website of the Company at https:// VC or OAVM (hereinafter referred collectively as “e-AGM www.marksanspharma.com/annual-reports.html, the website circulars”). The Members shall attend the AGM through VC by of the Stock Exchanges i.e., BSE Limited and National Stock following instructions annexed to this Notice. For the purpose Exchange of [Showing first 8,000 characters — download PDF for full document]